Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2017 · 10-Q
Revenue$50.11M$50.11M+131.2% vs Q3 2016 Net Income-$11.50M-$11.50MN/M vs Q3 2016 EPS Diluted-$0.13-$0.13N/M vs Q3 2016 Gross Profit$34,956,000+231.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$2,547,000N/M Free Cash Flowderived$2,003,000N/M Margins · derivedGross margin69.8%+21.1 pt vs Q3 2016
Operating margin-11.8%+118.6 pt vs Q3 2016
Net margin-22.9%+132.2 pt vs Q3 2016
ended Sep 30, 2017 · filed Oct 26, 2017 · 26 d after period end